BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36634615)

  • 1. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic features and its potential implication in bone oligometastatic NSCLC.
    Liao R; Yi G; Shen L; Zhang X; Xu Z; Peng Y; Yang Z
    BMC Pulm Med; 2023 Feb; 23(1):59. PubMed ID: 36755257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
    Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
    Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
    Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 8. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
    Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
    Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
    Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Genomic Landscape of
    Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
    Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
    Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
    J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
    Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
    Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
    Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
    Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
    Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
    Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.